S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)

Humacyte Stock Price, News & Analysis (NASDAQ:HUMA)

$2.66
+0.01 (+0.38%)
(As of 12/1/2023 ET)
Compare
Today's Range
$2.59
$2.84
50-Day Range
$1.99
$2.96
52-Week Range
$1.96
$5.60
Volume
851,573 shs
Average Volume
449,501 shs
Market Capitalization
$275.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.75

Humacyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
191.4% Upside
$7.75 Price Target
Short Interest
Bearish
8.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Humacyte in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$5.56 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.94) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Medical Sector

832nd out of 954 stocks

Biological Products, Except Diagnostic Industry

145th out of 159 stocks


HUMA stock logo

About Humacyte Stock (NASDAQ:HUMA)

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

HUMA Stock Price History

HUMA Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Instrument Name Humacyte Inc Instrument Symbol (HUMA-Q)
Q3 2023 Humacyte Inc Earnings Call
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Humacyte: Q3 Earnings Insights
Humacyte GAAP EPS of -$0.25 in-line
Humacyte Q3 2023 Earnings Preview
Humacyte's Earnings: A Preview
Stocks to Watch: Oracle, Acelyrin, Humacyte
See More Headlines
Receive HUMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/22/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HUMA
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.75
High Stock Price Target
$16.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+191.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-11,970,000.00
Pretax Margin
-286,051.63%

Debt

Sales & Book Value

Annual Sales
$1.57 million
Book Value
$0.36 per share

Miscellaneous

Free Float
79,649,000
Market Cap
$275.50 million
Optionable
Optionable
Beta
1.22
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Laura E. Niklason M.D. (Age 60)
    Ph.D., Founder, President, CEO & Director
    Comp: $717.85k
  • Mr. Dale A. Sander (Age 63)
    CFO, Chief Corporate Development Officer & Treasurer
    Comp: $667.45k
  • Dr. Shamik J. Parikh M.D. (Age 50)
    Chief Medical Officer
    Comp: $514.72k
  • Dr. Juliana L. Blum Ph.D.
    Co-Founder & Executive Advisor
  • Dr. Heather Ledbetter Prichard Ph.D. (Age 45)
    Chief Operating Officer
    Comp: $576.44k
  • Ms. Sabrina Osborne
    Executive Vice President of Business Strategy & People
  • Mr. William John Scheessele (Age 51)
    Chief Commercial Officer
  • Mr. Harold Alterson
    Senior Vice President of Quality
  • Dr. Yang Cao M.D. (Age 57)
    Ph.D., Chief Regulatory Officer














HUMA Stock Analysis - Frequently Asked Questions

Should I buy or sell Humacyte stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HUMA shares.
View HUMA analyst ratings
or view top-rated stocks.

What is Humacyte's stock price target for 2024?

3 brokerages have issued 12-month price objectives for Humacyte's shares. Their HUMA share price targets range from $3.00 to $16.00. On average, they anticipate the company's stock price to reach $7.75 in the next year. This suggests a possible upside of 191.4% from the stock's current price.
View analysts price targets for HUMA
or view top-rated stocks among Wall Street analysts.

How have HUMA shares performed in 2023?

Humacyte's stock was trading at $2.11 at the start of the year. Since then, HUMA stock has increased by 26.1% and is now trading at $2.66.
View the best growth stocks for 2023 here
.

Are investors shorting Humacyte?

Humacyte saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,090,000 shares, an increase of 10.7% from the October 31st total of 5,500,000 shares. Based on an average daily volume of 583,200 shares, the short-interest ratio is currently 10.4 days. Currently, 8.1% of the shares of the stock are short sold.
View Humacyte's Short Interest
.

When is Humacyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024.
View our HUMA earnings forecast
.

How were Humacyte's earnings last quarter?

Humacyte, Inc. (NASDAQ:HUMA) posted its earnings results on Thursday, November, 9th. The company reported ($0.25) EPS for the quarter, hitting analysts' consensus estimates of ($0.25).

What ETFs hold Humacyte's stock?

ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Clough Select Equity ETF (CBSE).Clough Long/Short Equity ETF (CBLS).

Who are Humacyte's major shareholders?

Humacyte's stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.50%), Charles Schwab Investment Management Inc. (0.44%), GSA Capital Partners LLP (0.34%), LPL Financial LLC (0.33%), Rokos Capital Management LLP (0.19%) and United Asset Strategies Inc. (0.14%). Insiders that own company stock include Brady W Dougan, Dale A Sander, Heather Ledbetter Prichard, Laura E Niklason, Michael T Constantino and William John Scheessele.
View institutional ownership trends
.

How do I buy shares of Humacyte?

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HUMA) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -